With regard to PAH [48, 79], FXR can inhibit the expression of the proinflammatory factor IL-6 and monocyte chemotactic protein-1 (MCP-1), as well as inhibit the NF-κB-mediated inflammatory response during PAH progression. Here, CCL2 is linked to pulmonary arterial hypertension.